Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5448)
All Articles published online
|
Sep 27, 2012 (publication date) through May 10, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Cabibbo G, Maida M, Genco C, Parisi P, Peralta M, Antonucci M, Brancatelli G, Cammà C, Craxì A, Di Marco V. Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study. World J Hepatol 2012; 4(9): 256-261 [PMID: 23060970 DOI: 10.4254/wjh.v4.i9.256] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v4/i9/256.htm |
| Number | Citing Articles |
| 1 |
Julie N. Leal, Mithat Gonen, Anne M. Covey, Joseph P. Erinjeri, George Getrajdman, Constantinos T. Sofocleous, Michael D’Angelica, Ronald P. DeMatteo, Ghassan K. Abou-Alfa, William R. Jarnagin, Yuman Fong, Karen T. Brown. Locoregional Therapy for Hepatocellular Carcinoma with and without Extrahepatic Spread. Journal of Vascular and Interventional Radiology 2015; 26(8): 1112 doi: 10.1016/j.jvir.2015.04.006
|
| 2 |
Jian-Jun Gao, Zhen-Yan Shi, Ju-Feng Xia, Yoshinori Inagaki, Wei Tang. Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma. World Journal of Gastroenterology 2015; 21(42): 12059-12070 doi: 10.3748/wjg.v21.i42.12059
|
| 3 |
Sharon W. Kwan, William P. Harris, Laura S. Gold, Paul L. Hebert. Comparative Effectiveness of Transarterial Embolization and Sorafenib for Hepatocellular Carcinoma: A Population-Based Study. American Journal of Roentgenology 2018; 210(6): 1359 doi: 10.2214/AJR.17.19094
|
| 4 |
Shuntaro Obi, Takahisa Sato, Shinpei Sato, Miho Kanda, Yuta Tokudome, Yuichiro Kojima, Yoji Suzuki, Kenji Hosoda, Toshihiro Kawai, Yuji Kondo, Yoshihiro Isomura, Hiroshi Ohyama, Keiko Nakagomi, Hiroshi Ashizawa, Yuko Miura, Hiroyuki Amano, Hitoshi Mochizuki, Masao Omata. The efficacy and safety of lenvatinib for advanced hepatocellular carcinoma in a real-world setting. Hepatology International 2019; 13(2): 199 doi: 10.1007/s12072-019-09929-4
|
| 5 |
Melanie B. Thomas, Elizabeth Garrett-Mayer, Munazza Anis, Kate Anderton, Tricia Bentz, Andie Edwards, Alan Brisendine, Geoffrey Weiss, Abby B. Siegel, Johanna Bendell, Ari Baron, Vinay Duddalwar, Anthony El-Khoueiry. A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma. Oncology 2018; 94(6): 329 doi: 10.1159/000485384
|
| 6 |
Feihang Wang, Shanshan Gao, Mengfei Wu, Danyang Zhao, Huiyi Sun, Sothea Yav, Yi Chen, Zihan Zhang, Minjie Yang, Yi Dong, Jianhua Wang, Xiaolin Wang, Zhiping Yan, Lingxiao Liu. The prognostic role of the AST/ALT ratio in hepatocellular carcinoma patients receiving thermal ablation combined with simultaneous TACE. BMC Gastroenterology 2023; 23(1) doi: 10.1186/s12876-023-02719-1
|
| 7 |
Shishira Bharadwaj, Tushar D Gohel. Perspectives of physicians regarding screening patients at risk of hepatocellular carcinoma. Gastroenterology Report 2016; 4(3): 237 doi: 10.1093/gastro/gou089
|
| 8 |
Won-Mook Choi, Su Jong Yu, Hongkeun Ahn, Hyeki Cho, Young Youn Cho, Minjong Lee, Jeong-ju Yoo, Yuri Cho, Dong Hyeon Lee, Eun Ju Cho, Jeong-Hoon Lee, Yoon Jun Kim, Jung-Hwan Yoon. A model to estimate survival in ambulatory patients with hepatocellular carcinoma: Can it predict the natural course of hepatocellular carcinoma?. Digestive and Liver Disease 2017; 49(11): 1273 doi: 10.1016/j.dld.2017.07.007
|
| 9 |
Ying-Fen Hong, Zhan-Hong Chen, Xiao-Kun Ma, Xing Li, Dong-Hao Wu, Jie Chen, Min Dong, Li Wei, Tian-Tian Wang, Dan-Yun Ruan, Ze-Xiao Lin, Jing-Yun Wen, Qu Lin, Chang-Chang Jia, Xiang-Yuan Wu. Comparison of five models for end-stage liver disease in predicting the survival rate of patients with advanced hepatocellular carcinoma. Tumor Biology 2016; 37(4): 5265 doi: 10.1007/s13277-015-4366-2
|
| 10 |
Shi-zhong Yang, Wei Zhang, Wei-sheng Yuan, Jia-hong Dong. Recurrence of Hepatocellular Carcinoma With Epithelial–Mesenchymal Transition After Spontaneous Regression. Medicine 2015; 94(28): e1062 doi: 10.1097/MD.0000000000001062
|
| 11 |
Giuseppe Cabibbo, Salvatore Petta, Marcello Maida, Calogero Cammà. Sorafenib for Hepatocellular Carcinoma: From Randomized Controlled Trials to Clinical Practice. Digestive Diseases 2015; 33(5): 668 doi: 10.1159/000438477
|
| 12 |
Guergana Panayotova, Keri E Lunsford, Nyan L Latt, Flavio Paterno, James V Guarrera, Nikolaos Pyrsopoulos. Expanding indications for liver transplantation in the era of liver transplant oncology. World Journal of Gastrointestinal Surgery 2021; 13(5): 392-405 doi: 10.4240/wjgs.v13.i5.392
|
| 13 |
Bruna Scaggiante, Rosella Farra, Barbara Dapas, Gabriele Baj, Gabriele Pozzato, Mario Grassi, Fabrizio Zanconati, Gabriele Grassi. Aptamer targeting of the elongation factor 1A impairs hepatocarcinoma cells viability and potentiates bortezomib and idarubicin effects. International Journal of Pharmaceutics 2016; 506(1-2): 268 doi: 10.1016/j.ijpharm.2016.04.031
|
| 14 |
Maria Reig, Alejandro Forner, Jordi Rimola, Joana Ferrer-Fàbrega, Marta Burrel, Ángeles Garcia-Criado, Robin K. Kelley, Peter R. Galle, Vincenzo Mazzaferro, Riad Salem, Bruno Sangro, Amit G. Singal, Arndt Vogel, Josep Fuster, Carmen Ayuso, Jordi Bruix. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. Journal of Hepatology 2022; 76(3): 681 doi: 10.1016/j.jhep.2021.11.018
|
| 15 |
Clemens Schotten, Lars P. Bechmann, Paul Manka, Jens Theysohn, Alexander Dechêne, Amr El Fouly, Francesco Barbato, Ursula Neumann, Sonia Radünz, Svenja Sydor, Dominik Heider, Marino Venerito, Ali Canbay, Guido Gerken, Ken Herrmann, Heiner Wedemeyer, Jan Best. NAFLD-Associated Comorbidities in Advanced Stage HCC Do Not Alter the Safety and Efficacy of Yttrium-90 Radioembolization. Liver Cancer 2019; 8(6): 491 doi: 10.1159/000501484
|
| 16 |
Edoardo G. Giannini, Fabio Farinati, Francesca Ciccarese, Anna Pecorelli, Gian Lodovico Rapaccini, Mariella Di Marco, Luisa Benvegnù, Eugenio Caturelli, Marco Zoli, Franco Borzio, Maria Chiaramonte, Franco Trevisani. Prognosis of untreated hepatocellular carcinoma. Hepatology 2015; 61(1): 184 doi: 10.1002/hep.27443
|
| 17 |
Natalia Khalaf, Jun Ying, Sahil Mittal, Sarah Temple, Fasiha Kanwal, Jessica Davila, Hashem B. El-Serag. Natural History of Untreated Hepatocellular Carcinoma in a US Cohort and the Role of Cancer Surveillance. Clinical Gastroenterology and Hepatology 2017; 15(2): 273 doi: 10.1016/j.cgh.2016.07.033
|
| 18 |
Jin-feng Zhang, Zhi-jun Shu, Chun-yi Xie, Qi Li, Xi-hong Jin, Wei Gu, Fang-jian Jiang, Chang-quan Ling, William B. Coleman. Prognosis of Unresectable Hepatocellular Carcinoma: Comparison of Seven Staging Systems (TNM, Okuda, BCLC, CLIP, CUPI, JIS, CIS) in a Chinese Cohort. PLoS ONE 2014; 9(3): e88182 doi: 10.1371/journal.pone.0088182
|
| 19 |
Stefano Colagrande, Andrea L Inghilesi, Sami Aburas, Gian G Taliani, Cosimo Nardi, Fabio Marra. Challenges of advanced hepatocellular carcinoma. World Journal of Gastroenterology 2016; 22(34): 7645-7659 doi: 10.3748/wjg.v22.i34.7645
|
| 20 |
Po-Da Chen, Chiung-Nien Chen, Rey-Heng Hu, Hong-Shiee Lai. Clinical experience of double primary gastric cancer and hepatocellular carcinoma. Formosan Journal of Surgery 2017; 50(1): 10 doi: 10.4103/fjs.fjs_9_17
|
| 21 |
Thomas Ward, Jason Gordon, Beverley Jones, Hayley Bennett, Samantha Webster, Anupama Kalsekar, Yong Yuan, Michael Brenner, Phil McEwan. Value of Sustained Virologic Response in Patients with Hepatitis C as a Function of Time to Progression of End-Stage Liver Disease. Clinical Drug Investigation 2017; 37(1): 61 doi: 10.1007/s40261-016-0458-z
|
| 22 |
Ashwaq Alolyan, Kanan Alshammari, Mohammad Arabi, Ahmed Alshehri, Hamad Alsuhaibani, Fahad Ibnshamsah, Abdullah Alsharm, Mervat Mahrous, Adnan Al Zanbagi, Mazen Hassanain, Shouki Bazarbashi. Treatment Patterns and Recommendations for Improving the Management of Hepatocellular Carcinoma in Saudi Arabia. Journal of Hepatocellular Carcinoma 2024; : 349 doi: 10.2147/JHC.S442842
|
| 23 |
Giuseppe Cabibbo, Silvia Tremosini, Giovanni Galati, Giancarlo Mazza, Gennaro Gadaleta-Caldarola, Giuseppe Lombardi, Michela Antonucci, Rodolfo Sacco. Transarterial chemoembolization and sorafenib in hepatocellular carcinoma. Expert Review of Anticancer Therapy 2014; 14(7): 831 doi: 10.1586/14737140.2014.920694
|
| 24 |
Fabrizia Gelardi, Marcello Rodari, Cristiano Pini, Roberta Zanca, Alessia Artesani, Giovanni Tosi, Arturo Chiti, Martina Sollini. ALBI grade for outcome prediction in patients affected by hepatocellular carcinoma treated with transarterial radioembolization. Frontiers in Nuclear Medicine 2022; 2 doi: 10.3389/fnume.2022.934446
|
| 25 |
Jasem Albarrak, Humaid Al-Shamsi. Current Status of Management of Hepatocellular Carcinoma in The Gulf Region: Challenges and Recommendations. Cancers 2023; 15(7): 2001 doi: 10.3390/cancers15072001
|
| 26 |
Teerapat Ungtrakul, Chulabhorn Mahidol, Pattra Chun-on, Charlie Laohapand, Surachate Siripongsakun, Akeanong Worakitsitisatorn, Sirachat Vidhayakorn, Wariya Boonchuay, Jiraporn Dechma, Gaidganok Sornsamdang, Kamonwan Soonklang, Tassanee Sriprayoon, Tawesak Tanwandee, Chirayu U Auewarakul. Hepatocellular carcinoma screening and surveillance in 2293 chronic hepatitis B patients in an endemic area. World Journal of Gastroenterology 2016; 22(34): 7806-7812 doi: 10.3748/wjg.v22.i34.7806
|
| 27 |
Brian I. Carr, Petr Pancoska, Edoardo G. Giannini, Fabio Farinati, Francesca Ciccarese, Gian Ludovico Rapaccini, Maria Di Marco, Luisa Benvegnù, Marco Zoli, Franco Borzio, Eugenio Caturelli, Maria Chiaramonte, Franco Trevisani. Identification of Two Clinical Hepatocellular Carcinoma Patient Phenotypes From Results of Standard Screening Parameters. Seminars in Oncology 2014; 41(3): 406 doi: 10.1053/j.seminoncol.2014.04.002
|
| 28 |
Giuseppe Cabibbo, Marcello Maida, Calogero Cammà, Antonio Craxì. Is the efficacy of sorafenib treatment in patients with hepatocellular carcinoma affected by age?. Expert Review of Anticancer Therapy 2013; 13(12): 1355 doi: 10.1586/14737140.2013.859989
|
| 29 |
Martha M Kirstein, Torsten Voigtländer, Nora Schweitzer, Jan B Hinrichs, Jens Marquardt, Marcus‐Alexander Wörns, Roman Kloeckner, Thorben W Fründt, Harald Ittrich, Frank Wacker, Thomas Rodt, Michael P Manns, Henning Wege, Arndt Weinmann, Arndt Vogel. Transarterial chemoembolization versus sorafenib in patients with hepatocellular carcinoma and extrahepatic disease. United European Gastroenterology Journal 2018; 6(2): 238 doi: 10.1177/2050640617716597
|
| 30 |
Rodolfo Sacco, Michela Antonucci, Irene Bargellini, Sara Marceglia, Valeria Mismas, Giuseppe Cabibbo. Transarterial chemoembolization and sorafenib in patients with intermediate-stage hepatocellular carcinoma: time to enter routine clinical practice?. Future Oncology 2015; 11(17): 2371 doi: 10.2217/fon.15.173
|
| 31 |
V. V. Breder, M. U. Pitkevich, E. R. Virshke, L. A. Kostyakova, I. A. Dzhanyan, K. K. Laktionov. BCLC-B hepatocellular carcinoma treatment or when should the systemic therapy be started. Medical Council 2018; (10): 27 doi: 10.21518/2079-701X-2018-10-27-32
|
| 32 |
David J. Pinato, Madhava Pai, Isabella Reccia, Markand Patel, Alexandros Giakoustidis, Georgios Karamanakos, Azelea Rushd, Shiraz Jamshaid, Alberto Oldani, Glenda Grossi, Mario Pirisi, Paul Tait, Rohini Sharma. Preliminary qualification of a novel, hypoxic-based radiologic signature for trans-arterial chemoembolization in hepatocellular carcinoma. BMC Cancer 2018; 18(1) doi: 10.1186/s12885-018-4120-4
|
| 33 |
Jan Erik Slotta, Otto Kollmar, Volker Ellenrieder, B Michael Ghadimi, Kia Homayounfar. Hepatocellular carcinoma: Surgeon's view on latest findings and future perspectives. World Journal of Hepatology 2015; 7(9): 1168-1183 doi: 10.4254/wjh.v7.i9.1168
|
| 34 |
Tanita Suttichaimongkol, Manoon Mitpracha, Kawin Tangvoraphonkchai, Phuangphaka Sadee, Kittisak Sawanyawisuth, Wattana Sukeepaisarnjaroen. Clinical versus radiographical factors associated with hepatocellular carcinoma diagnosis in high-risk patients: sizes matter. Future Science OA 2022; 8(4) doi: 10.2144/fsoa-2021-0108
|
| 35 |
Koichiro Yamakado, Shiro Miyayama, Shozo Hirota, Kimiyoshi Mizunuma, Kenji Nakamura, Yoshitaka Inaba, Satoshi Yamamoto, Kunihiro Matsuo, Norifumi Nishida, Takeshi Aramaki, Hiroshi Anai, Shinichi Kora, Shigeo Oikawa, Ken Watanabe, Taku Yasumoto, Kinya Furuichi, Masato Yamaguchi. Prognosis of patients with intermediate-stage hepatocellular carcinomas based on the Child-Pugh score: subclassifying the intermediate stage (Barcelona Clinic Liver Cancer stage B). Japanese Journal of Radiology 2014; 32(11): 644 doi: 10.1007/s11604-014-0358-1
|
| 36 |
Andrea R. Mospan, Heather L. Morris, Michael W. Fried. Real‐world evidence in hepatocellular carcinoma. Liver International 2021; 41(S1): 61 doi: 10.1111/liv.14864
|
| 37 |
Sweta Soni, Puneet Pareek, Satya narayan, Amrita Rakesh, Abhilasha Abhilasha. Hepatocellular Carcinoma (HCC) in North-Western India: A Retrospective Study Focusing on Epidemiology, Risk Factors, and Survival. Journal of Gastrointestinal Cancer 2022; 53(4): 921 doi: 10.1007/s12029-021-00712-z
|
| 38 |
Hyun-seok Kim, Hashem B. El-Serag. The Epidemiology of Hepatocellular Carcinoma in the USA. Current Gastroenterology Reports 2019; 21(4) doi: 10.1007/s11894-019-0681-x
|
| 39 |
Bo-Wen Zhuang, Wei Li, Bin Qiao, Nan Zhang, Man-Xia Lin, Wei Wang, Ming Kuang, Ming-De Lu, Xiao-Yan Xie, Xiao-Hua Xie. Preoperative prognostic value of alfa-fetoprotein density in patients with hepatocellular carcinoma undergoing radiofrequency ablation. International Journal of Hyperthermia 2022; 39(1): 1143 doi: 10.1080/02656736.2022.2116491
|
| 40 |
Zai‐Shang Li, Antonio Augusto Ornellas, Christian Schwentner, Xiang Li, Alcides Chaux, Georges Netto, Arthur L. Burnett, Yong Tang, JiunHung Geng, Kai Yao, Xiao‐Feng Chen, Bin Wang, Hong Liao, Nan Liu, Peng Chen, Yong‐Hong Lei, Qi‐Wu Mi, Hui‐Lan Rao, Ying‐Ming Xiao, Qi‐Lin Wang, Zi‐Ke Qin, Zhuo‐Wei Liu, Yong‐Hong Li, Zi‐Jun Zou, Jun‐Hang Luo, Hui Li, Hui Han, Fang‐Jian Zhou. A modified clinicopathological tumor staging system for survival prediction of patients with penile cancer. Cancer Communications 2018; 38(1): 1 doi: 10.1186/s40880-018-0340-x
|
| 41 |
Hyo Jung Cho, Geum Ok Baek, Chul Won Seo, Hye Ri Ahn, Suna Sung, Ju A Son, Soon Sun Kim, Sung Won Cho, Jeong Won Jang, Suk Woo Nam, Jae Youn Cheong, Jung Woo Eun. Exosomal microRNA‐4661‐5p–based serum panel as a potential diagnostic biomarker for early‐stage hepatocellular carcinoma. Cancer Medicine 2020; 9(15): 5459 doi: 10.1002/cam4.3230
|
| 42 |
Per Lindnér, Erik Holmberg, Magnus Rizell, Larsolof Hafström. Staging and therapy for patients with hepatocellular cancer in a defined population from 2000 to 2011 – active palliative treatment improved overall survival. Acta Oncologica 2016; 55(3): 297 doi: 10.3109/0284186X.2015.1080857
|
| 43 |
C. Rory Goodwin, Vijay Yanamadala, Alejandro Ruiz-Valls, Nancy Abu-Bonsrah, Ganesh Shankar, Eric W. Sankey, Christine Boone, Michelle J. Clarke, Mark Bilsky, Ilya Laufer, Charles Fisher, John H. Shin, Daniel M. Sciubba. A Systematic Review of Metastatic Hepatocellular Carcinoma to the Spine. World Neurosurgery 2016; 91: 510 doi: 10.1016/j.wneu.2016.04.026
|
| 44 |
Christopher D. Woodrell, Lissi Hansen, Thomas D. Schiano, Nathan E. Goldstein. Palliative Care for People With Hepatocellular Carcinoma, and Specific Benefits for Older Adults. Clinical Therapeutics 2018; 40(4): 512 doi: 10.1016/j.clinthera.2018.02.017
|
| 45 |
Manoj Kumar, Dipanjan Panda. Role of Supportive Care for Terminal Stage Hepatocellular Carcinoma. Journal of Clinical and Experimental Hepatology 2014; 4: S130 doi: 10.1016/j.jceh.2014.03.049
|
| 46 |
Saad Saffo, Tamar H. Taddei. Systemic Management for Advanced Hepatocellular Carcinoma: A Review of the Molecular Pathways of Carcinogenesis, Current and Emerging Therapies, and Novel Treatment Strategies. Digestive Diseases and Sciences 2019; 64(4): 1016 doi: 10.1007/s10620-019-05582-x
|
| 47 |
ZHANGGUI WANG, WEIDONG HAN, XINBING SUI, YONG FANG, HONGMING PAN. Autophagy: A novel therapeutic target for hepatocarcinoma (Review). Oncology Letters 2014; 7(5): 1345 doi: 10.3892/ol.2014.1916
|
| 48 |
Hye Kyong Park, Sang Soo Lee, Chang Bin Im, Changjo Im, Ra Ri Cha, Wan Soo Kim, Hyun Chin Cho, Jae Min Lee, Hyun Jin Kim, Tae Hyo Kim, Woon Tae Jung, Ok-Jae Lee. Hepatitis C virus genotype affects survival in patients with hepatocellular carcinoma. BMC Cancer 2019; 19(1) doi: 10.1186/s12885-019-6040-3
|
| 49 |
Masashi Mizumoto, Yoshiko Oshiro, Toshiyuki Okumura, Kuniaki Fukuda, Nobuyoshi Fukumitsu, Masato Abei, Hitoshi Ishikawa, Kayoko Ohnishi, Haruko Numajiri, Koji Tsuboi, Hideyuki Sakurai. Association between pretreatment retention rate of indocyanine green 15 min after administration and life prognosis in patients with HCC treated by proton beam therapy. Radiotherapy and Oncology 2014; 113(1): 54 doi: 10.1016/j.radonc.2014.08.015
|
| 50 |
Chiara Genco, Giuseppe Cabibbo, Marcello Maida, Giuseppe Brancatelli, Massimo Galia, Nicola Alessi, Giuseppe Butera, Claudio Genova, Piero Romano, Maurizio Raineri, Antonello Giarratano, Massimo Midiri, Calogero Cammà. Treatment of hepatocellular carcinoma: present and future. Expert Review of Anticancer Therapy 2013; 13(4): 469 doi: 10.1586/era.13.21
|
| 51 |
Robert Elliott, Sathya Ram, Vinit Khanna. Classification and Current Treatment of Hepatocellular Carcinoma. American Journal of Interventional Radiology 2018; 2: 8 doi: 10.25259/AJIR-21-2018
|
| 52 |
H. Taflin, L. Hafström, E. Holmberg, M. Castedal, P. Lindnér. The impact of increased immigration to Sweden on the incidence and treatment of patients with HCC and underlying liver disease. Scandinavian Journal of Gastroenterology 2019; 54(6): 746 doi: 10.1080/00365521.2019.1627580
|
| 53 |
Seikan Hai, Etsuro Hatano, Toshihiro Okada, Naoki Uyama, Kazuhiro Suzumura, Jiro Fujimoto. Is Noncurative Hepatic Resection Justified for Advanced Hepatocellular Carcinoma?. The American Surgeon 2018; 84(12): 1938 doi: 10.1177/000313481808401241
|
| 54 |
Shintaro Shiba, Takanori Abe, Kei Shibuya, Hiroyuki Katoh, Yoshinori Koyama, Hirohumi Shimada, Satoru Kakizaki, Ken Shirabe, Hiroyuki Kuwano, Tatsuya Ohno, Takashi Nakano. Carbon ion radiotherapy for 80 years or older patients with hepatocellular carcinoma. BMC Cancer 2017; 17(1) doi: 10.1186/s12885-017-3724-4
|
| 55 |
Marcello Maida, Massimo Iavarone, Maurizio Raineri, Calogero Cammà, Giuseppe Cabibbo. Second line systemic therapies for hepatocellular carcinoma: Reasons for the failure. World Journal of Hepatology 2015; 7(17): 2053-2057 doi: 10.4254/wjh.v7.i17.2053
|
| 56 |
Lei Xu, Lin Chen, Wei Zhang. Neoadjuvant treatment strategies for hepatocellular carcinoma. World Journal of Gastrointestinal Surgery 2021; 13(12): 1550-1566 doi: 10.4240/wjgs.v13.i12.1550
|
| 57 |
Shuling Chen, Zhenwei Peng, Mengchao Wei, Weifeng Liu, Zihao Dai, Haibo Wang, Jie Mei, Mingfong Cheong, Hanmei Zhang, Ming Kuang. Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis. BMC Cancer 2018; 18(1) doi: 10.1186/s12885-018-4308-7
|
| 58 |
Yen-Yang Chen, Chih-Chi Wang, Yueh-Wei Liu, Wei-Feng Li, Yen-Hao Chen. Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib. PeerJ 2020; 8: e10382 doi: 10.7717/peerj.10382
|